EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Clinical features, treatment, and follow-up of OPPG and high-bone-mass disorders: LRP5 is a key regulator of bone mass

Na Ren, Shanshan Lv, Xiang Li, Chong Shao, Ziyuan Wang, Yazhao Mei, Wendi Yang, Wenzhen Fu, Yunqiu Hu, Ling Sha, Weiwei Hu, Zhenlin Zhang und 1 weitere

Osteoporosis International · 2024

DOI: 10.1007/s00198-024-07080-x ↗

Kurz gefasst

Fallbericht in der Zeitschrift Osteoporosis International, 2024. Verfasst von Na Ren und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Osteoporosis and Bone Disease, Shanghai Clinical Research Center of Bone Disease, Sixth People's Hospital Affiliated to Shanghai Jiao T…. Hauptthemen laut MEDLINE: Low Density Lipoprotein Receptor-Related Protein-5, Bone Density, Bone Density Conservation Agents, Mutation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Key Technologies Research and Development Program, National Natural Science Foundation of China, Innovative Research Group Project of the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Low Density Lipoprotein Receptor-Related Protein-5Bone DensityBone Density Conservation AgentsMutationDiphosphonatesHumansFemaleMaleAdultFollow-Up StudiesOsteogenesis ImperfectaAdolescentYoung AdultMiddle AgedChild

Stichwörter der Autor:innen

LRP5High bone massLRP5-HBMOPPGOsteoporosisWnt

Substanzen

Low Density Lipoprotein Receptor-Related Protein-5LRP5 protein, humanBone Density Conservation AgentsDiphosphonates

Autor:innen und Institutionen

  • Department of Osteoporosis and Bone Disease, Shanghai Clinical Research Center of Bone Disease, Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Yishan Road 600, Shanghai, 200233,…

Förderung

  • Key Technologies Research and Development Program
  • National Natural Science Foundation of China
  • Innovative Research Group Project of the National Natural Science Foundation of China

Zitieren

APA

Ren, N., Lv, S., Li, X., Shao, C., Wang, Z., Mei, Y., Yang, W., Fu, W., Hu, Y., Sha, L., Hu, W., Zhang, Z., & Wang, C. (2024). Clinical features, treatment, and follow-up of OPPG and high-bone-mass disorders: LRP5 is a key regulator of bone mass. Osteoporosis International. https://doi.org/10.1007/s00198-024-07080-x

Vancouver

Ren N, Lv S, Li X, Shao C, Wang Z, Mei Y, et al. Clinical features, treatment, and follow-up of OPPG and high-bone-mass disorders: LRP5 is a key regulator of bone mass. Osteoporosis International. 2024. doi:10.1007/s00198-024-07080-x

BibTeX
@article{Ren2024,
  author = {Ren, Na and Lv, Shanshan and Li, Xiang and Shao, Chong and Wang, Ziyuan and Mei, Yazhao and Yang, Wendi and Fu, Wenzhen and Hu, Yunqiu and Sha, Ling and Hu, Weiwei and Zhang, Zhenlin and Wang, Chun},
  title = {Clinical features, treatment, and follow-up of OPPG and high-bone-mass disorders: LRP5 is a key regulator of bone mass},
  journal = {Osteoporosis International},
  year = {2024},
  doi = {10.1007/s00198-024-07080-x}
}
Kostenlos starten →